Beth K Potter

List of Publications by Year
in descending order

83 papers	1,914 citations	304368 22 h-index	301761 39 g-index
86 all docs	86 docs citations	86 times ranked	3171 citing authors

#	Article	IF	Citations
1	Reporting Guidelines for Survey Research: An Analysis of Published Guidance and Reporting Practices. PLoS Medicine, 2011, 8, e1001069.	3.9	284
2	Does a relationship exist between body weight, concerns about weight, and smoking among adolescents? An integration of the literature with an emphasis on gender. Nicotine and Tobacco Research, 2004, 6, 397-425.	1.4	168
3	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. American Journal of Gastroenterology, 2017, 112, 1412-1422.	0.2	88
4	Cannabisâ€based products for pediatric epilepsy: A systematic review. Epilepsia, 2019, 60, 6-19.	2.6	79
5	A systematic review of the association between coping strategies and quality of life among caregivers of children with chronic illness and/or disability. BMC Pediatrics, 2019, 19, 215.	0.7	63
6	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	1.5	48
7	Exploring informed choice in the context of prenatal testing: findings from a qualitative study. Health Expectations, 2008, 11, 355-365.	1.1	46
8	Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?. Genetics in Medicine, 2016, 18, 117-123.	1.1	40
9	A quality assessment of Health Management Information System (HMIS) data for maternal and child health in Jimma Zone, Ethiopia. PLoS ONE, 2019, 14, e0213600.	1.1	40
10	Metabolomics of prematurity: analysis of patterns of amino acids, enzymes, and endocrine markers by categories of gestational age. Pediatric Research, 2014, 75, 367-373.	1.1	39
11	Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet Journal of Rare Diseases, 2016, 11, 168.	1.2	38
12	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet Journal of Rare Diseases, 2016, 11, 12.	1.2	38
13	Socioeconomic status and non-fatal injuries among Canadian adolescents: variations across SES and injury measures. BMC Public Health, 2005, 5, 132.	1.2	37
14	Accurate prediction of gestational age using newborn screening analyte data. American Journal of Obstetrics and Gynecology, 2016, 214, 513.e1-513.e9.	0.7	37
15	Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. Journal of Pediatrics, 2017, 184, 165-171.e1.	0.9	34
16	Factors associated with knowledge of and satisfaction with newborn screening education: a survey of mothers. Genetics in Medicine, 2012, 14, 963-970.	1.1	31
17	Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Systematic Reviews, 2019, 8, 27.	2.5	30
18	Achieving the â€œtriple aimâ€•for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genetics in Medicine, 2013, 15, 415-422.	1.1	29

#	Article	IF	Citations
19	Consent for newborn screening: parentsâ€™ and health-care professionalsâ€™ experiences of consent in practice. European Journal of Human Genetics, 2016, 24, 1530-1534.	1.4	29
20	Postnatal Prediction of Gestational Age Using Newborn Fetal Hemoglobin Levels. EBioMedicine, 2017, 15, 203-209.	2.7	27
21	Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. Journal of Inherited Metabolic Disease, 2016, 39, 139-147.	1.7	26
22	The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatrics, 2010, 10, 82.	0.7	25
23	Guidance for considering ethical, legal, and social issues in health technology assessment: Application to genetic screening. International Journal of Technology Assessment in Health Care, 2008, 24, 412-422.	0.2	24
24	Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians. Journal of Inherited Metabolic Disease, 2012, 35, 115-123.	1.7	24
25	False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use. Pediatrics, 2017, 140, .	1.0	24
26	Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 18-22.	0.9	24
27	Migraine and Mental Health in a Population-Based Sample of Adolescents. Canadian Journal of Neurological Sciences, 2017, 44, 44-50.	0.3	22
28	Using newborn screening analytes to identify cases of neonatal sepsis. Scientific Reports, 2017, 7, 18020.	1.6	21
29	Scoping review of patient- and family-oriented outcomes and measures for chronic pediatric disease. BMC Pediatrics, 2015, 15, 7.	0.7	20
30	Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada. BMC Women's Health, 2018, 18, 134.	0.8	20
31	Newborn screening education on the internet: a content analysis of North American newborn screening program websites. Journal of Community Genetics, 2011, 2, 127-134.	0.5	19
32	The use of relative incidence ratios in self-controlled case series studies: an overview. BMC Medical Research Methodology, 2016, 16, 126.	1.4	19
33	Newborn Blood Spot Screening in Four Countries: Stakeholder Involvement. Journal of Public Health Policy, 2008, 29, 121-142.	1.0	18
34	External validation of postnatal gestational age estimation using newborn metabolic profiles in Matlab, Bangladesh. ELife, 2019, 8, .	2.8	18
35	Benefits and burdens of newborn screening: public understanding and decision-making. Personalized Medicine, 2014, 11, 593-607.	0.8	17
36	Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases. Orphanet Journal of Rare Diseases, 2018, 13, 104.	1.2	16

#	Article	IF	Citations
37	Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. Pediatrics, 2021, 148, .	1.0	16
38	Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. Orphanet Journal of Rare Diseases, 2020, 15, 12.	1.2	15
39	Mental Health Screening and Differences in Access to Care among Prisoners. Canadian Journal of Psychiatry, 2018, 63, 692-700.	0.9	14
40	Mental health treatment patterns following screening at intake to prison.. Journal of Consulting and Clinical Psychology, 2018, 86, 15-23.	1.6	14
41	Performance of a postnatal metabolic gestational age algorithm: a retrospective validation study among ethnic subgroups in Canada. BMJ Open, 2017, 7, e015615.	0.8	13
42	Developments in evidence creation for treatments of inborn errors of metabolism. Journal of Inherited Metabolic Disease, 2021, 44, 88-98.	1.7	13
43	Is there value in using physician billing claims along with other administrative health care data to document the burden of adolescent injury? An exploratory investigation with comparison to self-reports in Ontario, Canada. BMC Health Services Research, 2005, 5, 15.	0.9	12
44	Yield and Efficiency of Mental Health Screening: A Comparison of Screening Protocols at Intake to Prison. PLoS ONE, 2016, 11, e0154106.	1.1	12
45	Attitudes to incorporating genomic risk assessments into population screening programs: the importance of purpose, context and deliberation. BMC Medical Genomics, 2016, 9, 25.	0.7	12
46	Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease. Kidney International Reports, 2018, 3, 691-700.	0.4	12
47	Neurologistsâ€™ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 118-126.	0.9	12
48	Health-care providersâ€™ perspectives on uncertainty generated by variant forms of newborn screening targets. Genetics in Medicine, 2020, 22, 566-573.	1.1	11
49	Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study. Epilepsy and Behavior, 2020, 111, 107120.	0.9	11
50	Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: lessons learned from the Canadian Inherited Metabolic Diseases Research Network. Orphanet Journal of Rare Diseases, 2020, 15, 89.	1.2	11
51	Screening for depression in children and adolescents: a protocol for a systematic review update. Systematic Reviews, 2021, 10, 24.	2.5	11
52	Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children. Research Involvement and Engagement, 2021, 7, 66.	1.1	11
53	A comparison of measures of socioeconomic status for adolescents in a Canadian national health survey. Chronic Diseases in Canada, 2005, 26, 80-9.	0.9	11
54	Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations. Pharmacoeconomics, 2019, 37, 1261-1276.	1.7	10

#	Article	IF	Citations
55	Incidental screen positive findings in a prospective cohort study in Matlab, Bangladesh: insights into expanded newborn screening for low-resource settings. Orphanet Journal of Rare Diseases, 2019, 14, 25.	1.2	10
56	Education and Parental Involvement in Decisionâ€Making About Newborn Screening: Understanding Goals to Clarify Content. Journal of Genetic Counseling, 2015, 24, 400-408.	0.9	9
57	A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. Genetics in Medicine, 2017, 19, 403-411.	1.1	9
58	Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys. Trials, 2017, 18, 603.	0.7	9
59	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet Journal of Rare Diseases, 2019, 14, 70.	1.2	9
60	Utilization of key preventive measures for pregnancy complications and malaria among women in Jimma Zone, Ethiopia. BMC Public Health, 2019, 19, 1443.	1.2	9
61	Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research. Orphanet Journal of Rare Diseases, 2021, 16, 26.	1.2	9
62	Association between newborn screening analytes and hypoxic ischemic encephalopathy. Scientific Reports, 2019, 9, 15704.	1.6	8
63	Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. Pharmacoeconomics, 2020, 38, 971-980.	1.7	8
64	Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Systematic Reviews, 2019, 8, 75.	2.5	7
65	Parental psychosocial aspects and stressors involved in the management of inborn errors of metabolism. Molecular Genetics and Metabolism Reports, 2020, 25, 100654.	0.4	7
66	Health Care for Mitochondrial Disorders in Canada: A Survey of Physicians. Canadian Journal of Neurological Sciences, 2019, 46, 717-726.	0.3	6
67	Metabolic Clinic Atlas: Organization of Care for Children with Inherited Metabolic Disease in Canada. JIMD Reports, 2014, 21, 15-22.	0.7	3
68	Seasonal variation in rates of emergency room visits and acute admissions following recommended infant vaccinations in Ontario, Canada: A self-controlled case series analysis. Vaccine, 2014, 32, 7148-7153.	1.7	3
69	Decision curve analysis as a framework to estimate the potential value of screening or other decisionâ€making aids. International Journal of Methods in Psychiatric Research, 2018, 27, .	1.1	3
70	T-cell receptor excision circle levels and safety of paediatric immunization: A population-based self-controlled case series analysis. Human Vaccines and Immunotherapeutics, 2018, 14, 1378-1391.	1.4	3
71	Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveys. Trials, 2021, 22, 816.	0.7	3
72	Blood metals and vitamin D status in a pregnancy cohort: A bidirectional biomarker analysis. Environmental Research, 2022, 211, 113034.	3.7	3

#	Article	IF	Citations
73	What is in a Name? Parent, Professional and Policy-Maker Conceptions of Consent-Related Language in the Context of Newborn Screening. Public Health Ethics, 2019, 12, 158-175.	0.4	2
74	Family History Taking in Pediatric Practice: A Qualitative Interview Study. Public Health Genomics, 2019, 22, 110-118.	0.6	2
75	Association between newborn screening analyte profiles and infant mortality. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 835-838.	0.7	2
76	A Retrospective Cohort Study Investigating the Impact of Maternal Pre-Pregnancy Body Mass Index on Pediatric Health Service Utilization. Journal of Obstetrics and Gynaecology Canada, 2021, 43, 1267-1273.	0.3	2
77	External validation of machine learning models including newborn metabolomic markers for postnatal gestational age estimation in East and South-East Asian infants. Gates Open Research, 2020, 4, 164.	2.0	2
78	Mental Health Screening, Treatment, and Institutional Incidents: A Propensity Score Matched Analysis of Long-Term Outcomes of Screening. International Journal of Forensic Mental Health, 2018, 17, 133-144.	0.6	1
79	Family Experiences with Care for Children with Inherited Metabolic Diseases in Canada: A Cross-Sectional Survey. Patient, 2022, 15, 171-185.	1.1	1
80	Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening. BMC Pediatrics, 2021, 21, 296.	0.7	1
81	Methodological challenges in measuring meaningful change in individuals with spinal muscular atrophy. Muscle and Nerve, 2021, 64, 639-640.	1.0	0
82	Familiesâ€™ healthcare experiences for children with inherited metabolic diseases: protocol for a mixed methods cohort study. BMJ Open, 2022, 12, e055664.	0.8	0
83	Patient Engagement in a Multi-Stakeholder Workshop to Plan the Collection of Patient-Oriented Outcomes for Children with Inherited Metabolic Diseases. Healthcare Quarterly (Toronto, Ont), 2022, 24, 81-85.	0.3	0